Developing Novel Precision Oncology Therapeutics

We are a clinical-stage global biopharmaceutical company developing a pipeline of novel precision therapies for people with cancer.

About Us

Clinical Stage Assets

Taletrectinib
ROS1 inhibitor

ROS1-positive non-small cell lung cancer

Phase 2

Safusidenib
mIDH1 inhibitor

IDH1-mutant Grades 2 and 3 glioma, cholangiocarcinoma and other tumors

Phase 2

AB-329
axl inhibitor

Overcoming checkpoint inhibitor resistance in various tumors

Phase 1

Our Pipeline

Recent News

More News